Company

DEVELOPMENT
& HISTORY

NUVISAN - A fully integrated CRO / CDMO since 1979

2019

NUVISAN expended its portfolio to phase II patient trials by acquiring the CRO INAMED in Gauting near Munich.

2018

Market entry into Chemistry and Formulation development. NUVISAN acquired from NESTLÉ SKIN HEALTH parts of the GALDERMA research activities at Sophia Antipolis, France.

2017

Foundation of Nuvisan Inc., a subsidiary of NUVISAN GmbH, in Boston, Massachusetts USA.

2016

Entry into Non-Clinical development by the acquisition and integration oft he Grafing site from the long-standing partner Merck KGaA.

2011

Expansion to Waltrop Germany by taking over the research institute Essex Pharma from the MSD Group. Integration of large-scale stability programs and services. Expansion into pharmaceutical analysis of hormones, polymers and large molecules.

2010

Foundation as NUVISAN GmbH after sale of the AAIPharma group of companies to new owners.

2005

The company now traded under the name AAIPharma Deutschland. The company was renamed AAIPharma in the USA at the same time as AAI International.

1997

Takeover by AAI International (Wilmington, NC). The company is a US-based multi-functional contract research organization providing GCP, GLP and GMP-related services to the pharmaceutical industry to support early to late product development.

1979

LAB GmbH was founded as one of the first German contract research institutions for the clinical development of the pharmaceutical industry. In the early clinical phase, the company quickly developed into a full-service provider.

International CRO/ CDMO with more than 40 years of experience.